Johnson & Johnson beats on top and bottom lines

Key Concepts:

• Tariffs on imports (specifically from China)
• Pharmaceutical and medical device manufacturing
• Johnson & Johnson (J&J) Q1 earnings
• Sales guidance
• Impact of tariffs on medtech and pharma
• US tax policy and its influence on manufacturing
• Public comment period

Johnson & Johnson Q1 Earnings and Sales Guidance:

• J&J beat expectations on both top and bottom lines in Q1.
• The company raised its full-year sales outlook by almost $2 billion, driven by its pharma portfolio.
• The increased sales guidance includes Caplyta, a bipolar disorder drug acquired through the recent acquisition of Intracellular.
• The full-year sales guidance is $91.4 billion.

Impact of Tariffs:

• The $91.4 billion sales guidance includes $400 million in tariff costs.
• The tariff impact is primarily on the medical device side, which represents about one-third of J&J's sales.
• J&J CFO Joe Wolk stated that the tariffs would be felt broadly across the medtech portfolio, not just on specific products or segments.
• The biggest impact currently is on products of US origin being shipped into China.
• The current guidance does not include potential tariffs on pharmaceuticals.

Trump Administration Probe and Potential Pharma Tariffs:

• The Trump administration announced a probe into imports, potentially leading to tariffs on medicines.
• J&J was expecting this probe.
• J&J has been communicating to the administration that shifting pharma production is not a quick process (weeks or months).
• J&J is already planning to increase pharmaceutical production in the US.

Manufacturing in the US and Tax Policy:

• Like other pharma companies, J&J has started building more manufacturing facilities in the US since the 2017 tax cuts.
• J&J CEO Joaquin Delgado stated that tax policy, not tariffs, is the most effective way to increase pharma and medtech manufacturing in the US.
• J&J, Lilly, Merck, and Novartis have all highlighted their investments in US manufacturing in recent months.

Public Comment Period:

• A three-week public comment period has been initiated, allowing the industry to present its case against the proposed tariffs.

Conclusion:

J&J's Q1 performance was strong, but the company is facing potential headwinds from tariffs, particularly on its medtech business. While J&J is taking steps to mitigate the impact by increasing US manufacturing, the company believes that tax policy is a more effective tool than tariffs for promoting domestic production. The upcoming public comment period provides an opportunity for the industry to advocate against the proposed tariffs.